It was noted that IL-1 secretion preceded IL-6 production by several hours, and treatment with the IL-1 receptor inhibitor anakinra was equally effective as the IL-6 receptor inhibitor tocilizumab in treating CRS in this model. The gene discussed is IL1A; the disease is congenital rubella syndrome.